A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics
and an automated voxel-based procedure, is presented and validated in a large data set …

This multicenter study examined 18 F-FDG PET measures in the differential diagnosis of
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB…

The prognostic value of 18 F‐fluorodeoxyglucose (FDG) positron emission tomography (PET)
in the assessment of post‐treatment residual masses in patients with Hodgkin's disease (…

Orbitofrontal metabolic impairment is characteristic of the frontal variant of frontotemporal
dementia (fv-FTD), as are early changes in emotional and social conduct. Two main types of …

BACKGROUND: Alzheimer’s disease (AD) is clinically characterized by cognitive impairment
and behavioral disturbances. The aim of the study was to identify regional alterations in …

We explored the neural substrate of anosognosia for cognitive impairment in Alzheimer's
disease (AD). Two hundred nine patients with mild to moderate dementia and their caregivers …

Background The standard uptake value (SUV) approach in oncological positron emission
tomography has known shortcomings, all of which affect the reliability of the SUV as a …

Objective: Functional brain correlates of remission in patients with major depressive
disorder (MDD) are measured with positron emission tomography (PET) and 18 F‐…

Purpose To evaluate the feasibility of PET/MRI (positron emission tomography/magnetic
resonance imaging) with FDG ( 18 F-fluorodeoxyglucose) for initial staging of head and neck …

Aim: Evaluation of a dedicated software tool for automatic delineation of 3D regions of
interest in oncological PET. Patients, methods: The applied procedure encompasses …